STING 激动剂的发展及其作为癌症免疫疗法的新成果。
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
机构信息
Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL, 60605, USA.
Pritzker School of Medicine, University of Chicago Medicine, Chicago, IL, USA.
出版信息
Curr Oncol Rep. 2023 Mar;25(3):189-199. doi: 10.1007/s11912-023-01361-0. Epub 2023 Jan 27.
PURPOSE OF REVIEW
New therapies are needed to potentiate the effects of current immunotherapies and overcome resistance. The stimulator of interferon genes genes (STING) pathway is an innate immune activating cascade that may enhance current cancer immunotherapies.
RECENT FINDINGS
Preclinical data has shown that the addition of a STING agonist enhances the effect of current treatments such as immune checkpoint inhibitor antibodies and radiation therapy. Early phase trials have demonstrated modest efficacy of STING agonists and revealed new mechanistic and technical challenges. STING agonists are a new class of agents that activate the immune response to improve tumor control. A wide range of preclinical experiments, translational data, and ongoing clinical trials support the therapeutic use of STING agonists in patients. Trials to determine optimal drug combinations and novel delivery mechanisms are continuing in development.
目的综述
需要新的疗法来增强当前免疫疗法的效果并克服耐药性。干扰素基因刺激物（STING）途径是一种先天免疫激活级联反应，可能增强当前的癌症免疫疗法。
最近的发现
临床前数据表明，添加 STING 激动剂可增强当前治疗方法的效果，如免疫检查点抑制剂抗体和放射治疗。早期临床试验表明 STING 激动剂具有适度的疗效，并揭示了新的机制和技术挑战。STING 激动剂是一类新型药物，可激活免疫反应以改善肿瘤控制。广泛的临床前实验、转化数据和正在进行的临床试验支持 STING 激动剂在患者中的治疗用途。正在开发中进行确定最佳药物组合和新型输送机制的试验。
Zotero 插件